Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.02, 2.01, 8.01, 9.01 · 8-K

Chrome Holding Co.

Termination of a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Other Events

Item 1.02 Termination of a Material Definitive Agreement As previously disclosed, on March 23, 2025, 23andMe Holding Co., a Delaware corporation (the “Company”), and certain of its subsidiaries (collectively, the “Filing Subsidiaries” and, together with the Company, the “Debtors”) filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code (the “Bankr…

Filed Jul 14, 2025Accepted Jul 14, 2025, 7:13 AM EDTCIK 1804591Accession 0001193125-25-158551
Share

Company context

23andMe is a genetics-led consumer healthcare company empowering a healthier future. For more information, please visit www.23andme.com.

Historical securities (5)

Recent company filings

  1. 15-12G filingDec 4, 2025
  2. Bankruptcy or ReceivershipDec 4, 2025
  3. Other EventsNov 17, 2025
  4. NT 10-Q filingNov 7, 2025
  5. Regulation FD DisclosureNov 4, 2025

Disclosure sections

Items 1.02, 2.01, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.02Item 1.02 - Termination of Material Agreement
Item 1.02 Termination of a Material Definitive Agreement As previously disclosed, on March 23, 2025, 23andMe Holding Co., a Delaware corporation (the “Company”), and certain of its subsidiaries (collectively, the “Filing Subsidiaries” and, together with the Company, the “Debtors”) filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court (the “Court”) for the Eastern District of Missouri (the “Chapter 11 Cases”). On July 14, 2025, in connection with the consummation of the Transaction (as defined below), the Debtors repaid in full all outstanding indebtedness and terminated all commitments and obligations under that certain Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement (as amended, restated, supplemented or otherwise modified and in effect prior to the date hereof) with JMB Capital Partners Lending, LLC.
Item 2.01Item 2.01 - Completion of Acquisition
Item 2.01 Completion of Acquisition or Disposition of Assets The information set forth under Item 8.01 of this Current Report on Form 8-K related to the Transaction is incorporated by reference into this Item 2.01.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events As previously disclosed, on June 13, 2025, the Debtors and TTAM Research Institute, a California nonprofit public benefit corporation (“TTAM”), entered into the Asset Purchase Agreement (as amended, restated, supplemented or otherwise modified and in effect prior to the date hereof, the “TTAM Asset Purchase Agreement”). TTAM is an affiliate of Anne Wojcicki, the Company’s co-founder, former chief executive officer, and current member of the Company’s Board of Directors. Pursuant to the TTAM Asset Purchase Agreement, TTAM agreed to acquire substantially all of the Debtors’ assets, including all of the properties, rights, title, interests and other tangible intangible assets that the Debtors own or possess (the “Assets”), excluding the Excluded Assets (as defined in the TTAM Asset Purchase Agreement), free and clear of liens, claims, encumbrances, and other interests other than certain permitted encumbrances, to assume certain specified liabilities of the Debtors, and to pay amounts necessary to cure defaults (subject to an agreed cap), if any, under contracts to be assumed and assigned to TTAM (such assumed liabilities and cure payments, the “Liabilities”). TTAM agreed to acquire the Assets for a total purchase price of $305.0 million in cash, in addition to the assumption and payment of the Liabilities, subject to the terms and conditions set forth in the TTAM Asset Purchase Agreement (such transaction contemplated by the TTAM Asset Purchase Agreement, the “Transaction”). In addition, TTAM agreed to serve as a stalking horse sponsor of a chapter 11 plan to acquire the Company’s telehealth services business that provides medical care, pharmacy fulfillment, and the lab and test ordering services operated by Lemonaid Health, Inc. (the “Excluded Business”) for an aggregate purchase price of $2.5 million. The Excluded Assets comprise primarily of the assets of the Excluded Business. As previously disclosed, on June 13, 2025, the Debtors filed the Notice of Winning Bidder with Respect to the Final Proposal Procedures to Acquire the Debtors’ Assets with the Court. As previously disclosed, on June 27, 2025, the Court entered an order (the “Order”) (i) authorizing and approving the Company’s entry into the TTAM Asset Purchase Agreement, pursuant to which TTAM agreed to acquire the Assets, excluding the Excluded Assets and (ii) granting related relief. On July 14, 2025, the Company and TTAM consummated the Transaction. The financial impact to the Company of the Transaction will be reflected in the monthly operating reports of the Company commencing with the monthly report for the month of July 2025. The Chapter 11 Cases remain pending, and the Company expects to provide additional information regarding the distribution of proceeds from the Transaction, if any, at a subsequent date. A copy of the press release announcing the consummation of the Transaction is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference. Additional Information on the Chapter 11 Cases Court filings and information about the Chapter 11 Cases, including the TTAM Asset Purchase Agreement, can be found at a website maintained by the Company’s claims agent Kroll at https://restructuring.ra.kroll.com/23andMe, by calling (888) 367-7556, or by sending an email to 23andMeInfo@ra.kroll.com. The documents and other information available via website or elsewhere are not part of this Current Report on Form 8-K and shall not be deemed incorporated herein. Cautionary Note Regarding the Company’s Common Stock The Company cautions that trading in the Company’s Class A common stock, $0.0001 par value per share (the “Common Stock”) during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company’s Common Stock may bear little or no relationship to the actual recovery, if any, by holders of the Common Stock in the Chapter 11 Cases. The Company cannot assure investors of the liquidity of an active trading market, the ability to sell shares of the Common Stock when desired, or the prices that an investor may obtain for the shares of the Common Stock. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical fact, included or incorporated in this document are forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “predicts,” “continue,” “will,” “schedule,” and “would” or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on the Company’s current expectations and projections about future events and various assumptions. The Company cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of the Company), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements, which could include the following: risks and uncertainties relating to the Chapter 11 Cases, including but not limited to, the Company’s ability to obtain Court approval with respect to motions in the Chapter 11 Cases, the effects of the Chapter 11 Cases on the Company and on the interests of various constituents, Court rulings in the Chapter 11 Cases and the outcome of the Chapter 11 Cases in general, the length of time the Company will operate under the Chapter 11 Cases, risks associated with any third-party motions in the Chapter 11 Cases, the potential adverse effects of the Chapter 11 Cases on the Company’s liquidity or results of operations and increased legal and other professional costs necessary to execute the Company’s reorganization; whether the Company will emerge, in whole or in part, from the Chapter 11 Cases as a going concern; trading price and volatility of the Common Stock; and the continuation of trading of the Common Stock on the OTC Pink Market, including whether broker-dealers will continue to provide public quotes of the Common Stock on the OTC Pink Market, whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market, and whether quotes for the Common Stock will continue on this market in the future. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the SEC, and as revised and updated by the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this document and, except as may be required by law, the Company undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
Filed exhibits (1)
EX-99.1 (by filename) d11473dex991.htm

EX-99.1 2 d11473dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets SAN FRANCISCO - July 14, 2025 - TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and founded and led by Anne Wojcicki, today announced that it has completed the acquisition of the Personal Genome Service (PGS) and Research Services business lines of 23andMe Holding Co. (together with its debtor subsidiaries, the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, under Section 363 of the U.S. Bankruptcy Code. As part of TTAM, 23andMe is continuing to operate and provide customers with personalized DNA testing and research services. TTAM is committed to providing customers with choice and transparency with their data, including the option to change their decision on whether to participate in research. Additional information regarding the Company’s Chapter 11 filing, proceedings and claims process is available at https://restructuring.ra.kroll.com/23andMe. Questions about the claims process should be directed to the Company’s claims agent, Kroll, at 23a…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.